Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this Study is to Assess Safety and Pharmacokinetics of megavec 400 mg
(Imatinib mesylate) under Fasted Conditions in Healthy Male Subjects.